Selected research
Industry Research
Cancer Drugs Industry Research Report 2026
Market perspective
The global Cancer Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Cancer Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Cancer Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Cancer Drugs include Takeda, Eisai, Teva, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Cancer Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cancer Drugs Market by Company
Takeda
Eisai
Teva
Sanofi
Johnson & Johnson
Novartis
Roche
Eli Lilly
Pfizer
Bayer
Amgen
AbbVie
AstraZeneca
Otsuka
Merck KGaA
Merck & Co.
Ipsen
Gilead Sciences
Celgene
Bristol-Myers Squibb
Biogen Idec
Astellas
Cancer Drugs Segment by Type
Targeted Therapy
Hormonal Therapy (Biologic Therapy)
Chemotherapy
Immunotherapy
Others
Cancer Drugs Segment by Application
Blood Cancer
Gastrointestinal Cancer
Breast Cancer
Prostate Cancer
Respiratory/Lung Cancer
Other Cancers
Cancer Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cancer Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cancer Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cancer Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Targeted Therapy
- Hormonal Therapy (Biologic Therapy)
- Chemotherapy
- Immunotherapy
- Others
Applications
- Blood Cancer
- Gastrointestinal Cancer
- Breast Cancer
- Prostate Cancer
- Respiratory/Lung Cancer
- Other Cancers
Companies covered
- Takeda
- Eisai
- Teva
- Sanofi
- Johnson & Johnson
- Novartis
- Roche
- Eli Lilly
- Pfizer
- Bayer
- Amgen
- AbbVie
- AstraZeneca
- Otsuka
- Merck KGaA
- Merck & Co.
- Ipsen
- Gilead Sciences
- Celgene
- Bristol-Myers Squibb
- Biogen Idec
- Astellas
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cancer Drugs Market Size (2021-2032)
- 2.2.2 Global Cancer Drugs Sales (2021-2032)
- 2.2.3 Global Cancer Drugs Market Average Price (2021-2032)
- 2.3 Cancer Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Targeted Therapy
- 2.3.3 Hormonal Therapy (Biologic Therapy)
- 2.3.4 Chemotherapy
- 2.3.5 Immunotherapy
- 2.3.6 Others
- 2.4 Cancer Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Blood Cancer
- 2.4.3 Gastrointestinal Cancer
- 2.4.4 Breast Cancer
- 2.4.5 Prostate Cancer
- 2.4.6 Respiratory/Lung Cancer
- 2.4.7 Other Cancers
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cancer Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cancer Drugs Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Cancer Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Cancer Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Cancer Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cancer Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cancer Drugs, Product Type & Application
- 3.8 Global Manufacturers of Cancer Drugs, Established Date
- 3.9 Global Cancer Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Cancer Drugs Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Eisai
- 4.2.1 Eisai Company Information
- 4.2.2 Eisai Business Overview
- 4.2.3 Eisai Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eisai Cancer Drugs Product Portfolio
- 4.2.5 Eisai Recent Developments
- 4.3 Teva
- 4.3.1 Teva Company Information
- 4.3.2 Teva Business Overview
- 4.3.3 Teva Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Teva Cancer Drugs Product Portfolio
- 4.3.5 Teva Recent Developments
- 4.4 Sanofi
- 4.4.1 Sanofi Company Information
- 4.4.2 Sanofi Business Overview
- 4.4.3 Sanofi Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sanofi Cancer Drugs Product Portfolio
- 4.4.5 Sanofi Recent Developments
- 4.5 Johnson & Johnson
- 4.5.1 Johnson & Johnson Company Information
- 4.5.2 Johnson & Johnson Business Overview
- 4.5.3 Johnson & Johnson Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Johnson & Johnson Cancer Drugs Product Portfolio
- 4.5.5 Johnson & Johnson Recent Developments
- 4.6 Novartis
- 4.6.1 Novartis Company Information
- 4.6.2 Novartis Business Overview
- 4.6.3 Novartis Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novartis Cancer Drugs Product Portfolio
- 4.6.5 Novartis Recent Developments
- 4.7 Roche
- 4.7.1 Roche Company Information
- 4.7.2 Roche Business Overview
- 4.7.3 Roche Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Roche Cancer Drugs Product Portfolio
- 4.7.5 Roche Recent Developments
- 4.8 Eli Lilly
- 4.8.1 Eli Lilly Company Information
- 4.8.2 Eli Lilly Business Overview
- 4.8.3 Eli Lilly Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly Cancer Drugs Product Portfolio
- 4.8.5 Eli Lilly Recent Developments
- 4.9 Pfizer
- 4.9.1 Pfizer Company Information
- 4.9.2 Pfizer Business Overview
- 4.9.3 Pfizer Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Pfizer Cancer Drugs Product Portfolio
- 4.9.5 Pfizer Recent Developments
- 4.10 Bayer
- 4.10.1 Bayer Company Information
- 4.10.2 Bayer Business Overview
- 4.10.3 Bayer Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bayer Cancer Drugs Product Portfolio
- 4.10.5 Bayer Recent Developments
- 4.11 Amgen
- 4.11.1 Amgen Company Information
- 4.11.2 Amgen Business Overview
- 4.11.3 Amgen Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Amgen Cancer Drugs Product Portfolio
- 4.11.5 Amgen Recent Developments
- 4.12 AbbVie
- 4.12.1 AbbVie Company Information
- 4.12.2 AbbVie Business Overview
- 4.12.3 AbbVie Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 AbbVie Cancer Drugs Product Portfolio
- 4.12.5 AbbVie Recent Developments
- 4.13 AstraZeneca
- 4.13.1 AstraZeneca Company Information
- 4.13.2 AstraZeneca Business Overview
- 4.13.3 AstraZeneca Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 AstraZeneca Cancer Drugs Product Portfolio
- 4.13.5 AstraZeneca Recent Developments
- 4.14 Otsuka
- 4.14.1 Otsuka Company Information
- 4.14.2 Otsuka Business Overview
- 4.14.3 Otsuka Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Otsuka Cancer Drugs Product Portfolio
- 4.14.5 Otsuka Recent Developments
- 4.15 Merck KGaA
- 4.15.1 Merck KGaA Company Information
- 4.15.2 Merck KGaA Business Overview
- 4.15.3 Merck KGaA Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Merck KGaA Cancer Drugs Product Portfolio
- 4.15.5 Merck KGaA Recent Developments
- 4.16 Merck & Co.
- 4.16.1 Merck & Co. Company Information
- 4.16.2 Merck & Co. Business Overview
- 4.16.3 Merck & Co. Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Merck & Co. Cancer Drugs Product Portfolio
- 4.16.5 Merck & Co. Recent Developments
- 4.17 Ipsen
- 4.17.1 Ipsen Company Information
- 4.17.2 Ipsen Business Overview
- 4.17.3 Ipsen Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Ipsen Cancer Drugs Product Portfolio
- 4.17.5 Ipsen Recent Developments
- 4.18 Gilead Sciences
- 4.18.1 Gilead Sciences Company Information
- 4.18.2 Gilead Sciences Business Overview
- 4.18.3 Gilead Sciences Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Gilead Sciences Cancer Drugs Product Portfolio
- 4.18.5 Gilead Sciences Recent Developments
- 4.19 Celgene
- 4.19.1 Celgene Company Information
- 4.19.2 Celgene Business Overview
- 4.19.3 Celgene Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Celgene Cancer Drugs Product Portfolio
- 4.19.5 Celgene Recent Developments
- 4.20 Bristol-Myers Squibb
- 4.20.1 Bristol-Myers Squibb Company Information
- 4.20.2 Bristol-Myers Squibb Business Overview
- 4.20.3 Bristol-Myers Squibb Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Bristol-Myers Squibb Cancer Drugs Product Portfolio
- 4.20.5 Bristol-Myers Squibb Recent Developments
- 4.21 Biogen Idec
- 4.21.1 Biogen Idec Company Information
- 4.21.2 Biogen Idec Business Overview
- 4.21.3 Biogen Idec Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 Biogen Idec Cancer Drugs Product Portfolio
- 4.21.5 Biogen Idec Recent Developments
- 4.22 Astellas
- 4.22.1 Astellas Company Information
- 4.22.2 Astellas Business Overview
- 4.22.3 Astellas Cancer Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.22.4 Astellas Cancer Drugs Product Portfolio
- 4.22.5 Astellas Recent Developments
5 Global Cancer Drugs Market Scenario by Region
- 5.1 Global Cancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cancer Drugs Sales by Region: 2021-2032
- 5.2.1 Global Cancer Drugs Sales by Region: 2021-2026
- 5.2.2 Global Cancer Drugs Sales by Region: 2027-2032
- 5.3 Global Cancer Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Cancer Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Cancer Drugs Revenue by Region: 2027-2032
- 5.4 North America Cancer Drugs Market Facts & Figures by Country
- 5.4.1 North America Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cancer Drugs Sales by Country (2021-2032)
- 5.4.3 North America Cancer Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cancer Drugs Market Facts & Figures by Country
- 5.5.1 Europe Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cancer Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Cancer Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cancer Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cancer Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cancer Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cancer Drugs Market Facts & Figures by Country
- 5.7.1 South America Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cancer Drugs Sales by Country (2021-2032)
- 5.7.3 South America Cancer Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Cancer Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cancer Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cancer Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cancer Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cancer Drugs Sales by Type (2021-2032)
- 6.1.1 Global Cancer Drugs Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Cancer Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Cancer Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Cancer Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cancer Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Cancer Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cancer Drugs Sales by Application (2021-2032)
- 7.1.1 Global Cancer Drugs Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Cancer Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Cancer Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Cancer Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cancer Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Cancer Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cancer Drugs Value Chain Analysis
- 8.1.1 Cancer Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cancer Drugs Production Mode & Process
- 8.2 Cancer Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cancer Drugs Distributors
- 8.2.3 Cancer Drugs Customers
9 Global Cancer Drugs Analyzing Market Dynamics
- 9.1 Cancer Drugs Industry Trends
- 9.2 Cancer Drugs Industry Drivers
- 9.3 Cancer Drugs Industry Opportunities and Challenges
- 9.4 Cancer Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst